T-Cell Lymphoma Market
Global T-Cell Lymphoma Market Size, Share & Trends Analysis Report by Type (Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult T-Cell Lymphoma, and Others) by Treatment Type (Radiotherapy, Chemotherapy, Targeted Therapy, Gene Therapy, and Others) Forecast, 2019-2025 Update Available - Forecast 2024-2030
The global T-Cell Lymphoma market is estimated to grow at a significant CAGR during the forecast period. T-cell lymphoma is a type of cancer, which forms in T cells, that is, immune system cells. Lymphocytes, a type of white blood cells are grown enormously in the body which leads to lymphoma or commonly called blood cancer. These lymphocytes severely affect the body such as blood, lymph node, spleen, bone marrow, and other organs, or even it can form a tumor. The diagnosis and treatment of the T-cell lymphoma depend on the type and stage of cancer. The key factors that drive the growth of the market include increasing incidences of lymphoma cancer owing to radiations, availability of a wide variety of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.
However, the costs associated with the treatment and drugs of cancer are likely to hamper the growth of the market. Nevertheless, government policies and initiatives regarding the cancer treatment of the patients are likely to create scope for the market during the forecast period. For instance, The Leukemia & Lymphoma Society's patient financial aid program offers financial assistance to the patients diagnosed with blood cancer, such as leukemia, lymphoma, or multiple myeloma. It offers treatment-related expenses for patients. Along with this, several other government initiatives are supporting the treatment of the patients.
Segmental Outlook
The global T-Cell Lymphoma market is segmented on the basis of type and treatment type. Based on the type, the market is segmented into peripheral T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, and others. Based on the treatment type, the market is segmented into radiotherapy, chemotherapy, therapy, and others such as targeted therapy.
Global -Cell Lymphoma Market Share by Therapy Type, 2018 (%)
Therapy Insights: Others Segment to Exhibit Significant Growth in the Market
Amongst the treatment type of the market, the other segment that include targeted therapy is estimated to e exhibit considerable growth in the market. The growth is attributed to the fact that it causes less harm as compared with other therapies. Targeted therapies involve the usage of drugs that block the growth and spread of the cancer cells by interfering with specific molecules that are responsible for the progression and spread of cancer cells. Targeted cancer therapies are often termed as molecularly targeted drugs, molecularly targeted therapies, precision medicines, or other similar names. This therapy is different from traditional chemotherapy. Chemotherapy destroys cancerous as well as healthy cells whereas targeted therapy only destroys the cancerous cell. Targeted therapy works by targeting specific genes or proteins. These genes and proteins are found in cancer cells or cells responsible for the growth of cancer.
Regional Outlook
The global T-Cell Lymphoma market is geographically segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold a significant share in the market during the forecast period. The factors that are contributing significantly to the regional growth of the market include increasing R&D activities, rising healthcare expenditure, and stringent government regulations related to medical facilities. According to the Organization for Economic Co-operation and Development (OECD), the US spends almost 17% of GDP on healthcare expenditure, whereas Canada spends around 11% of GDP on healthcare. Further, Asia-Pacific is also likely to hold a significant share in the market owing to the rising medical tourism in the economies such as India, Singapore among others.
Global T-Cell Lymphoma Market by Region, 2018 (%)
Market Players Outlook
Some of the prominent players operating in the global T-Cell Lymphoma market include Johnson & Johnson Services Inc., Novartis International AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Genmab A/S, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and others. These are the key companies adopting several organic and inorganic growth strategies such as product launches & developments, partnerships, agreements, and acquisitions to strengthen their product portfolios and maintain a competitive position in the global T-Cell Lymphoma market.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global T-Cell Lymphoma market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Strategy Analysis
3.2. Key Company Analysis
3.2.1. Spectrum Pharmaceuticals, Inc.
3.2.1.1. Overview
3.2.1.2. Financial Analysis
3.2.1.3. SWOT Analysis
3.2.1.4. Recent Developments
3.2.2. Johnson & Johnson Services Inc.
3.2.2.1. Overview
3.2.2.2. Financial Analysis
3.2.2.3. SWOT Analysis
3.2.2.4. Recent Developments
3.2.3. Seattle Genetics Inc.
3.2.3.1. Overview
3.2.3.2. Financial Analysis
3.2.3.3. SWOT Analysis
3.2.3.4. Recent Developments
3.2.4. Autolus Therapeutics PLC
3.2.4.1. Overview
3.2.4.2. Financial Analysis
3.2.4.3. SWOT Analysis
3.2.4.4. Recent Developments
3.2.5. Novartis International AG
3.2.5.1. Overview
3.2.5.2. Financial Analysis
3.2.5.3. SWOT Analysis
3.2.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global T-Cell Lymphoma Market by Type
5.1.1. Peripheral T-cell Lymphoma
5.1.2. Cutaneous T-cell Lymphoma
5.1.3. Anaplastic Large Cell Lymphoma
5.1.4. Angioimmunoblastic T-cell Lymphoma
5.1.5. Others (Adult T-Cell Lymphoma)
5.2. Global T-Cell Lymphoma Market by Treatment Type
5.2.1. Radiotherapy
5.2.2. Chemotherapy
5.2.3. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Actelion Pharmaceuticals Ltd.
7.2. Amgen Inc.
7.3. Autolus Therapeutics Plc
7.4. BioCryst Pharmaceuticals Inc.
7.5. Bristol-Myers Squibb Co.
7.6. Celgene Corp.
7.7. Cellerant Therapeutics, Inc.
7.8. Eisai Co. Ltd.
7.9. F. Hoffmann-La Roche Ltd.
7.10. Gilead Sciences, Inc.
7.11. GlaxoSmithKline PLC
7.12. Johnson & Johnson Services Inc.
7.13. Medivir AB
7.14. Merck & Co. Inc.
7.15. Novartis International AG
7.16. Pfizer Inc.
7.17. Sanofi SA
7.18. Seattle Genetics Inc.
7.19. Sorrento Therapeutics, Inc.
7.20. Spectrum Pharmaceuticals, Inc.
7.21. Takeda Pharmaceutical Co. Ltd.
1. GLOBAL T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
2. GLOBAL PERIPHERAL T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
3. GLOBAL CUTANEOUS T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
4. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
5. GLOBAL ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
6. GLOBAL OTHER T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
7. GLOBAL T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
8. GLOBAL RADIOTHERAPY FOR T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL CHEMOTHERAPY FOR T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL OTHER THERAPY FOR T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
12. NORTH AMERICAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
13. NORTH AMERICAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
14. NORTH AMERICAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
15. EUROPEAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
16. EUROPEAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
17. EUROPEAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
18. ASIA-PACIFIC T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
19. ASIA-PACIFIC T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
20. ASIA-PACIFIC T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
21. REST OF THE WORLD T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
22. REST OF THE WORLD T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
1. GLOBAL T-CELL LYMPHOMA MARKET SHARE BY TYPE, 2018 VS 2025 (%)
2. GLOBAL T-CELL LYMPHOMA MARKET SHARE BY TREATMENT TYPE, 2018 VS 2025 (%)
3. GLOBAL T-CELL LYMPHOMA MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
4. US T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
5. CANADA T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
6. UK T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
7. FRANCE T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
8. GERMANY T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
9. ITALY T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
10. SPAIN T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
11. ROE T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
12. INDIA T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
13. CHINA T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
14. JAPAN T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
15. REST OF ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF THE WORLD T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
